Skip to main content
Immuno-Biological Laboratories Co., Ltd. logo

Immuno-Biological Laboratories Co., Ltd. — Investor Relations & Filings

Ticker · 4570 ISIN · JP3921300004 T Manufacturing
Open in API
Filings indexed 65 across all filing types
Latest filing 2024-02-14 Interim / Quarterly Rep…
Country JP Japan
Listing T 4570

About Immuno-Biological Laboratories Co., Ltd.

https://www.ibl-japan.co.jp/en/

Immuno-Biological Laboratories (IBL) is a research and development-focused company that develops, manufactures, and supplies immunological research reagents and in-vitro diagnostic products for the global life sciences community. The company's core offerings include a comprehensive range of ELISA kits, antibodies, and cell culture-related products. IBL specializes in several key research areas, including aging, neurodegenerative disorders, kidney diseases, inflammatory diseases, and glucose/lipid metabolism. A notable proprietary technology is the LipoSEARCH® lipoprotein analyzing system, which uses patented GP-HPLC methods. The company also provides customized services to support specific research requirements.

Recent filings

Filing Released Lang Actions
四半期報告書－第42期第3四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan, as indicated by the header and the regulatory reference (Financial Instruments and Exchange Act). It contains detailed financial statements (balance sheets, income statements) for the third quarter of the 42nd fiscal year (April 1, 2023, to December 31, 2023). This fits the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-02-14 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is extremely short (597 characters) and contains a table structure typical of a cover page for a regulatory filing in Japan. Key elements include: "【提出書類】確認書" (Filing Document: Confirmation document), "【根拠条文】金融商品取引法第24条の４の８第１項" (Basis Article: Financial Instruments and Exchange Act Article 24-4-8 Paragraph 1), and a confirmation statement by the CEO regarding the appropriateness of the "四半期報告書" (Quarterly Report) for the second quarter (July 1 to September 30, 2023). Since this document is a *confirmation* of the quarterly report's accuracy, rather than the comprehensive quarterly report itself (which would be classified as IR), and given its brevity and focus on confirming regulatory compliance for a specific period, it most closely aligns with a regulatory confirmation or a specific type of interim filing documentation. However, none of the provided codes perfectly match a 'Quarterly Report Confirmation Document'. The closest related filing type is the Interim/Quarterly Report (IR). Given the context of Japanese filings, this confirmation document often accompanies or precedes the actual quarterly report submission. Since the document explicitly references the 'Quarterly Report' (四半期報告書) and covers a specific interim period, classifying it as an Interim/Quarterly Report (IR) is the most appropriate fit among the available options, assuming the confirmation is intrinsically linked to the submission of the IR itself. If it were purely an announcement of the IR release, RPA would apply, but this is a formal confirmation statement.
2023-11-14 Japanese
四半期報告書－第42期第2四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan, as indicated by the header and the regulatory reference (Financial Instruments and Exchange Act). It contains detailed financial statements, including the balance sheet and management analysis for the second quarter of the 42nd fiscal period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q2 2024
2023-11-14 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically confirming the accuracy of the contents of a Quarterly Report (Shihanki Hokokusho) for the first quarter of the 42nd fiscal period. Since this is a regulatory filing confirming the validity of a report rather than the quarterly report itself, and it does not fit into specific categories like 10-K or IR, it is classified as a general regulatory filing.
2023-08-14 Japanese
四半期報告書－第42期第1四半期(2023/04/01－2023/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, including the balance sheet and income statement for the first quarter of the 42nd fiscal year (April 1, 2023, to June 30, 2023). It includes management analysis, business risk assessments, and auditor review information. This fits the definition of an Interim/Quarterly Report (IR). Q1 2024
2023-08-14 Japanese
内部統制報告書－第41期(2022/04/01－2023/03/31)
Governance Information Classification · 100% confidence The document is titled '内部統制報告書' (Internal Control Report) and cites the Financial Instruments and Exchange Act (Article 24-4-4, Paragraph 1). It details the framework, scope, and results of the company's internal control over financial reporting. This type of document is a standalone audit-related regulatory filing concerning internal controls, which falls under the 'Audit Report / Information' category.
2023-06-30 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.